Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vanda Pharmaceuticals Inc (VNDA) Stock Forecast
Analysts expect Vanda Pharmaceuticals (VNDA) to earn -$2.52 per share in the fiscal year ending Dec 31, 2026, on revenue of $242.14M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 80.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 30.6%.
- Fiscal year ending Dec 31, 2026
- -$2.52
- EPS consensus, revenue $242.14M
- Fiscal year ending Dec 31, 2027
- -$0.74
- EPS consensus, revenue $316.26M
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.52 | -$2.61 to -$2.45 | 5 | $242.14M | $240.95M to $243.10M | 5 |
| Dec 31, 2027 | -$0.74 | -$1.47 to $0.07 | 5 | $316.26M | $286.40M to $342.50M | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.31 for the quarter ending Dec 31, 2026 to -$0.25 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.31 | -$0.38 to -$0.24 | 7 | $71.48M | $67.50M to $74.55M | 7 |
| Mar 31, 2027 | -$0.25 | -$0.32 to -$0.16 | 3 | $72.39M | $69.18M to $76.00M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.52 | -$3.03 | -$3.03 | -$3.02 | -$2.27 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.74 | -$0.96 | -$0.96 | -$1.03 | -$0.77 | N/A |
| Quarter ending Mar 31, 2027 | -$0.25 | -$0.41 | -$0.41 | -$0.44 | -$0.28 | N/A |
Frequently Asked Questions About VNDA
What is the VNDA stock forecast?
Consensus analyst estimates put Vanda Pharmaceuticals's EPS at -$2.52 for the fiscal year ending Dec 31, 2026, on revenue of $242.14M. The consensus rating from 5 analysts is Buy.
How do analysts rate VNDA stock?
Of 5 analysts covering Vanda Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VNDA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.52, with estimates from -$2.61 to -$2.45 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.74, with estimates from -$1.47 to $0.07 from 5 analysts.
What revenue do analysts expect from Vanda Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $242.14M, with estimates from $240.95M to $243.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $316.26M, with estimates from $286.40M to $342.50M.
How many analysts cover VNDA?
5 analysts rate Vanda Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VNDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts